Dr. Katharine Whartenby
Bone Marrow Transplantation Cancer Immunology
Assistant Professor of Oncology
Ph.D., University of Rochester, Rochester, NY
The research goals of the Whartenby lab are primarily to utilize the system of bone marrow transplantation with gene-modified bone marrow in order to induce antitumor immunity. A number of different strategies to inhibit and reverse the development of T- cell tolerance are being investigated. These findings are currently being further investigated for development into a clinical trial using gene-modified bone marrow differentiated into antigen presenting cells in vivo in order to induce antigen-specific immunity. Vaccination strategies for inducing antitumor immunity depend on effective antigen presentation. Studies are ongoing to identify the role of dendritic cell genes in the generation of tumor responses.
Baldwin, B. R., L. Li, K. F. Tse, S. Small, M. Collector, K. A. Whartenby, S. J. Sharkis, F. Racke, D. Huso, and D. Small. 2007. Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease. Leukemia 21:764-71.
Goldberg, M. V., C. H. Maris, E. L. Hipkiss, A. S. Flies, L. Zhen, R. M. Tuder, J. F. Grosso, T. J. Harris, D. Getnet, K. A. Whartenby, D. G. Brockstedt, T. W. Dubensky, Jr., L. Chen, D. M. Pardoll, and C. G. Drake. 2007. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 110:186-92.
Hu, L., M. Pennington, Q. Jiang, K. A. Whartenby, and P. A. Calabresi. 2007. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes. J Immunol 179:4563-70.
Huang, G. N., D. L. Huso, S. Bouyain, J. Tu, K. A. McCorkell, M. J. May, Y. Zhu, M. Lutz, S. Collins, M. Dehoff, S. Kang, K. Whartenby, J. Powell, D. Leahy, and P. F. Worley. 2008. NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science 319:476-81.
Huang, G.N., Huso, D.L., Bouyain, S., Tu, J., McCorkell, K.A., May, M.J., Zhu, Y., Lutz, M., Collins, S., Dehoff, M., Kang, S., Whartenby, K., Powell, J., Leahy, D., and Worley, P.F. (2008). NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science 319, 476-481.
Jones, M.V., Nguyen, T.T., Deboy, C.A., Griffin, J.W., Whartenby, K.A., Kerr, D.A., and Calabresi, P.A. (2008). Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis. J Neuroimmunol 199, 83-93.
Pan, F., L. Sun, D. B. Kardian, K. A. Whartenby, D. M. Pardoll, and J. O. Liu. 2007. Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin. Nature 445:433-6.
Whartenby, K. A., Calabresi, P. A., McCadden, E., Nguyen, B., Kardian, D., Wang, T., Mosse, C., Pardoll, D. M. & Small, D. (2005). Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci U S A 102, 16741-6.
Whartenby, K.A., Small, D., and Calabresi, P.A. (2008). FLT3 inhibitors for the treatment of autoimmune disease. Expert Opin Investig Drugs 17, 1685-1692.
Cui, Y., Kelleher, E., Straley, E., Fuchs, E., Gorski, K., Levitsky, H., et al. 2003. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat. Med. 9:952-958.